ClinicalTrials.gg
RecruitingNCT07850141Updated Nov 17, 2026

Prospective Registry of Exposure to Gepotidacin (PREG)

An observational study in Sexually Transmitted Diseases, sponsored by GlaxoSmithKline. Recruiting at 1 site in United States. Open to female participants aged 15 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by GlaxoSmithKline · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 17, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
614
Ages
15 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 283 studies in Sexually Transmitted Diseases with a site in United States — 32 open to participants now, 42 under way, 1 of them phase 3. Sexually Transmitted Diseases · United States.

Planned enrollment
11th of 30
614 · median 280
Started
2026
with 11 others
Observational
30 of 283
2 open now
Primary completion
2032-08
later than 41 of 41 live
Registered
282nd of 283
by date

Among the 283 studies in Sexually Transmitted Diseases with a site in United States, this one is the 11th largest by planned enrollment of the 30 observational ones that give a count, is one of 12 that started in 2026, is one of 30 observational ones, reaches primary completion later than 41 of the 41 other live ones, and was the 282nd registered.

Sexually Transmitted Diseases

525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.

Browse Sexually Transmitted Diseases studies →

Open to participants now

32 of the 283 studies in Sexually Transmitted Diseases with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Sexually Transmitted Diseases studies recruiting now, 30 (61%) set no upper age limit and 17 (35%) stop at 75 or younger; 23 take children under 18; 33 take healthy volunteers.

This study: 15 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Sexually Transmitted Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to monitor pregnancies exposed to gepotidacin and to evaluate possible teratogenic effects or birthweight-lowering effects of this medication relative to the primary outcomes of major congenital malformations (MCMs) and small for gestational age (SGA), as well as to evaluate secondary maternal, fetal, and infant outcomes.

03

Conditions studied

  • Sexually Transmitted Diseases

Keywords

  • Observational
  • Cohort
  • Gepotidacin
  • Urinary tract infections
  • Neonatal
  • Maternal
  • Pregnancy
04

Who can participate

Ages eligible
15 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant participants with uncomplicated urinary tract infection who are exposed to gepotidacin or standard-of-care antibiotics during the relevant exposure window.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Both cohorts:

  • Participants with aged 15 to 50 years
  • United States resident
  • Currently pregnant
  • Participants personally signed and dated document or, upon waiver of written consent by the relevant Institutional review board (IRB), verbal consent indicating that the participant (or a legally acceptable representative) has been informed of all pertinent aspects of the study
  • Authorization and contact information for the reporter (e.g., participant, maternal/infant Health care provider (HCP), prescriber) to allow for follow-up

Exposed cohort:

  • Exposed to gepotidacin at any time during pregnancy or the relevant exposure window

Comparator cohort:

  • Diagnosis of and treatment for uUTI at any time during pregnancy or the relevant comparator product exposure window
  • Exposed to one or more American College of Obstetricians and Gynecologists (ACOG)-recommended treatments for acute cystitis at any time during pregnancy or the relevant comparator product exposure window

Exclusion criteria

Exclusion Criteria:

For Both cohorts:

  • Diagnosis of known MCMs for the index pregnancy prior to enrollment

Exposed cohort:

  • None

Comparator cohort:

  • Exposure to gepotidacin at the time of enrollment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
614 participants (estimated)
Patient registry
No

Groups and cohorts

  • Exposed cohort

    Pregnant participants with uncomplicated urinary tract infection (uUTI) who are exposed to gepotidacin during the relevant exposure window

    Other: None (Observational study)

  • Comparator cohort

    Pregnant participants with uncomplicated urinary tract infection (uUTI) who are exposed to standard-of-care antibiotics during the relevant exposure window

    Other: None (Observational study)

Interventions

  • OtherNone (Observational study)

    Not Applicable since Observational Study

    Also known as: Observational Study

  • OtherNone (Observational study)

    Not Applicable since Observational Study

    Also known as: Observational Study

06

What researchers measure

Primary outcomes

  1. Number of infants with major congenital malformations (MCMs)

    An abnormality of body structure or function that is present at birth, is of prenatal origin (i.e., birth defect), has significant medical, social, or cosmetic consequences for the affected individual, and typically requires medical intervention.

    Time frame: At pregnancy outcome, with follow-up through 12 months after delivery

  2. Number of infants with small-for-gestational-age births (SGA)

    A newborn infant whose birth weight is less than (\<) 10th percentile for sex and gestational age using standard growth charts for full- and preterm live-born infants.

    Time frame: At live birth

Secondary outcomes

  1. Number of infants with minor congenital malformations

    An anomaly or abnormality of body structure that is present at birth, is of prenatal origin (i.e., birth defect), poses no significant health problem in the neonatal period, and tends to have limited social or cosmetic consequences for the affected individual.

    Time frame: At live Birth, with follow-up up through 12 months of age

  2. Number of participants (pregnant women) with pregnancy termination

    A voluntary fetal loss or interruption of pregnancy that occurs for any reason, including but not limited to for the preservation of maternal health or because of fetal abnormalities.

    Time frame: From date of conception (DOC) to <20 gestational weeks

  3. Number of participants (pregnant women) with spontaneous abortions (SAB)

    An involuntary fetal loss or the expulsion of the products of conception occurring at less than (\<) 20 gestational weeks.

    Time frame: From date of conception (DOC) to <20 gestational weeks

  4. Number of participants (pregnant women) with stillbirths

    Stillbirth is defined by the American College of Obstetricians and Gynecologists (ACOG), an involuntary fetal loss occurring at greater than or equal to (\>=) 20 weeks of gestation, or, if gestational age is unknown, a fetus weighing \>=350 grams.

    Time frame: From 20 weeks' gestation to pregnancy outcome

  5. Number of participants (pregnant women) with preeclampsia

    Preeclampsia is disorder of pregnancy associated with new-onset hypertension, which occurs most often after 20 weeks of gestation and frequently near term, and proteinuria, or, in the absence of proteinuria, it is defined as new-onset hypertension with the new onset of any of the following: Thrombocytopenia: platelet count \<100,000/milliliter (mL). Renal insufficiency: serum creatinine concentrations \>1.1 milligram per deciliter (mg/dL) or a doubling of the serum creatinine concentration in the absence of other renal disease. Impaired liver function: elevated blood concentrations of liver transaminases to twice the normal concentration. Pulmonary edema. New-onset headache unresponsive to medication and not accounted for by alternative diagnoses or visual symptoms

    Time frame: From 20 weeks' gestation to pregnancy outcome

  6. Number of participants (pregnant women) with eclampsia

    New-onset tonic-clonic, focal, or multifocal seizures in the absence of other causative conditions such as epilepsy, cerebral arterial ischemia and infarction, intracranial hemorrhage, or drug use.

    Time frame: From 20 weeks' gestation to pregnancy outcome

  7. Number of participants (pregnant women) with gestational hypertension

    Blood pressure greater than 140 millimeter of mercury (mmHg) systolic or 90 mmHg diastolic on 2 separate occasions at least 4 hours apart after 20 weeks of pregnancy when previous blood pressure was normal.

    Time frame: From 20 weeks' gestation to pregnancy outcome

  8. Number of participants (pregnant women) with gestational diabetes

    Any degree of glucose intolerance with onset or first recognition during pregnancy.

    Time frame: At pregnancy outcome

  9. Number of participants (pregnant women) with preterm births

    Preterm birth is defined as a live birth occurring at \<37 gestational weeks.

    Time frame: At live birth, if occurring before 37 gestational weeks

  10. Number of infants with postnatal growth deficiency

    Weight, length, or head circumference in \<10th percentile for sex and chronological age using standard growth charts

    Time frame: At 4 and 12 months of infant age

  11. Number of infants with developmental delay

    Failure to achieve the developmental milestones for chronological age, as defined by the Centers for Disease Control and Prevention.

    Time frame: At 4 and 12 months of infant age

07

Study locations

1 of 1 sites recruiting
  • PPD / Thermofisher
    Wilmington, North Carolina 28401, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Aug 2032, 70 months after the start.

Of 48 observational studies under Sexually Transmitted Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's planned 70 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2026
First posted
Sep 30, 2026
StartActual
Sep 30, 2026
Primary completionEst.
Aug 19, 2032
CompletionEst.
Aug 19, 2032
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
1 site added — first site in United States
Show site
  • PPD / Thermofisher · Wilmington, United States
Nov 17, 2026
Contact
Study contact changed: G•••@gsk.com · •••4466→P•••@thermofisher.com · •••0315. See the current contact
Nov 17, 2026
Registered
First appeared on the registry
Sep 30, 2026
Show all 2 updates
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • PPD / Thermofisher · Wilmington, United States
    Contact Study contact changed: G•••@gsk.com · •••4466→P•••@thermofisher.com · •••0315. See the current contact
    + 2 other changes: verification date and date precision
  2. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07850141
Lead sponsor
GlaxoSmithKline
Collaborators
PPD Observational Studies (part of Thermo Fisher Scientific, Inc.)
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Sep 30, 2026
Primary completion
Aug 19, 2032 (estimated)
Completion
Aug 19, 2032 (estimated)
Last update
Nov 17, 2026

Study contacts

PPD/ Thermofisher Call Center
Contact
PREGpregnancyregistry@thermofisher.com
1-877-371-0315
US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion